a5570593.htm
FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a - 16 under
the
Securities Exchange Act of 1934
ICON
plc
(Registrant’s
name)
0-29714
(Commission
file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland.
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Yes___X___ No_______
Indicate
by check mark whether the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___X___
Indicate
by check mark whether the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___X___
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes_______ No___X___
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):82
N/A
ICON
issues financial guidance for 2008 and reaffirms guidance for
2007.
(NASDAQ:ICLR)
Dublin,
Ireland, December 19, 2007 – ICON (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical, biotechnology and medical
device industries, today announced financial guidance for 2008.
2008
net
revenue is expected to be in the range of $750 - $770 million, compared to
a
range of $615 - $625 million which has already been guided for
2007.
2008
net
income per diluted share is forecast to be in the range of $2.27 - $2.36
compared to $1.82 - $1.85 guided for 2007.
The
company will hold a conference call today, December 19, 2007 at 09:00 EST [14:00
Ireland & UK]. A question and answer session will follow.
The
statements made in this Press Release may contain forward-looking statements
that involve a number of risks and uncertainties. In addition to the matters
described in this Press Release, the ability to maintain large client contracts
or enter into new contracts, maintain client relationships and the ability
to
manage the opening of new offices, the integration of new business mergers
and
acquisitions, as well as other risks and uncertainties detailed from time to
time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3,
may affect the actual results achieved by ICON. ICON disclaims any intent or
obligation to update these forward-looking statements.
The
financial information presented herein has been prepared in accordance with
U.S.
GAAP.
ICON
plc
is a global provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries. The Company specializes in the
strategic development, management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical studies. ICON
teams
have successfully conducted over 1,900 development projects and over 2,300
consultancy engagements across all major therapeutic areas. ICON currently
has
approximately 5,600 employees, operating from 67 locations in 35 countries.
Further information is available at www.iconplc.com.
Source:
ICON plc
Contact
:
Investor Relations 1-888-381-7923 or
Ciaran
Murray CFO + 353 –1-291-2000
Both
at
ICON.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
ICON
plc |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
|
Date: December
19, 2007
|
Ciaran
Murray
|